Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.

We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...

Despite higher expenses, including a net loss of $35.4 million in Q4 and a full-year loss of $110.0 million, the corporation is investing heavily in its clinical programs, particularly for VK2735 ...

For comparison, Roche's oral GLP-1 achieved 6.1% placebo-adjusted weight at the optimum dose in its phase 1 trial, while Viking's VK2735 – like Zepbound, a dual GLP-1 and GIP agonist – also ...

After hours: 7:59:53 pm GMT-5 ...